Sinopharm Taichi's in-development biologic drug semaglutide debuts at Canton Fair, launching global investment promotion
Guoyao Taiji's investigational drug semaglutide was showcased at the Canton Fair, initiating global investment outreach. The company has established API and formulation production facilities compliant with Chinese and US GMP standards, and the drug's raw material has completed US DMF filing. Separately, the Trump administration is reportedly considering an executive order to establish an AI task force for enhanced regulation, including a proposal for government review of new AI models, with White House officials briefing executives from Anthropic, Alphabet, and OpenAI on these plans. AI
IMPACT Potential US government regulation could shape the development and deployment of new AI models, impacting companies like OpenAI and Anthropic.